Building the evidentiary framework for pharmacogenetic testing: is it time to move beyond randomized controlled trials?
Author:
- 19 December 2012
- journal article
- Published by Taylor & Francis in Personalized Medicine
- Vol. 10 (1) , 1-3
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study designThe Pharmacogenomics Journal, 2011
- Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trialTrials, 2010
- Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trialThe Lancet, 2009
- Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38Circulation, 2008
- Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancerThe Lancet Oncology, 2008
- Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization EffectivenessJAMA, 2005
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004